Steady M&A Flow Lifts Fosun
Executive Summary
Continuing with its dual strategy driven by innovation and internationalization, Fosun Pharmaceutical recently announced two acquisitions on the trot. The deals separately tap into growth opportunities in new biologic products and build on Fosun’s presence in Africa.
You may also be interested in...
Arix And China's Fosun Ink A Strategic Partnership
A new strategic partnership has been forged between Arix Bioscience and China's Fosun International to develop new business opportunities in China.
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
Fosun Tweaks Gland Deal Amid Limbo In India
China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.